Article
Nutrition & Dietetics
Julia Martin-Virgala, Sara Fernandez-Villabrille, Beatriz Martin-Carro, Isaac Tamargo-Gomez, Juan F. Navarro-Gonzalez, Carmen Mora-Fernandez, Laura Calleros, Elena Astudillo-Cortes, Noelia Avello-Llano, Guillermo Marino, Adriana S. Dusso, Cristina Alonso-Montes, Sara Panizo, Jorge B. Cannata-Andia, Manuel Naves-Diaz, Natalia Carrillo-Lopez
Summary: This study investigated the potential role of sKlotho as an early biomarker in Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD). The findings indicated that sKlotho is a reliable indicator of kidney alpha-Klotho and may protect against osteogenic differentiation by increasing autophagy. Further studies are needed to explore the mechanisms of this potential protective effect.
Article
Transplantation
Lorenza Magagnoli, Mario Cozzolino, Fergus J. Caskey, Marie Evans, Claudia Torino, Gaetana Porto, Maciej Szymczak, Magdalena Krajewska, Christiane Drechsler, Peter Stenvinkel, Maria Pippias, Friedo W. Dekker, Esther N. M. de Rooij, Christoph Wanner, Nicholas C. Chesnaye, Kitty J. Jager
Summary: Chronic kidney disease-mineral and bone disorder (CKD-MBD) is common in older non-dialysis patients with advanced CKD. PTH and phosphate are independently associated with all-cause mortality, while only PTH is associated with cardiovascular mortality. Calcium does not have an independent association with mortality but modifies the effect of phosphate.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Biochemistry & Molecular Biology
Ting Sun, Xijie Yu
Summary: FGF23 is a new endocrine product that has been discovered in the past decade. It is not only related to bone diseases, but also plays a role in kidney and parathyroid metabolism, particularly as a biomarker and key factor in kidney diseases. FGF23 is upregulated in the early stages of chronic kidney disease (CKD), in response to excessive phosphorus levels. However, as kidney function declines, the protective effect of FGF23 weakens and can lead to various complications. Monoclonal antibodies targeting FGF23 are currently used to treat genetic diseases and CKD. This article reviews the role of FGF23 in CKD and discusses the interaction between FGF23 and various organs in CKD conditions, highlighting the importance of studying the effect of hyperphosphatemia on different organs. The potential of FGF23 for therapy is also discussed.
CURRENT MEDICINAL CHEMISTRY
(2023)
Article
Environmental Sciences
Ram B. Jain
Summary: Exposure to cadmium and lead can cause oxidative stress and result in kidney and cardiovascular diseases. The antiaging protein klotho acts as an antioxidant. This study found that the concentrations of klotho were affected by cadmium and lead exposure, with an observed decrease in klotho concentrations during kidney dysfunction, particularly with blood cadmium concentrations.
ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
(2022)
Article
Chemistry, Medicinal
Tao Lu, Mang Dou, Chengyi Yang, Qiangyan Hu, Yin'e Wang, Suxia Pan
Summary: This study aimed to investigate the role of Fucoidan in preventing CKD-MBD. It was found that Fucoidan can prevent CKD-MBD by up-regulating Klotho levels, and it has a renal protective effect by increasing the levels of 1,25 (OH)(2)D-3 in serum and alleviating kidney damage and fibrosis.
PHARMACOGNOSY MAGAZINE
(2023)
Article
Pharmacology & Pharmacy
Bu-Hui Liu, Fee-Lan Chong, Can-Can Yuan, Ying-Lu Liu, Hai-Ming Yang, Wen-Wen Wang, Qi-Jun Fang, Wei Wu, Mei-Zi Wang, Yue Tu, Zi-Yue Wan, Yi-Gang Wan, Guo-Wen Wu
Summary: This study demonstrated that FPS and CTR had beneficial effects in alleviating renal dysfunction and damage, improving calcium-phosphorus metabolic disorder and bone lesion in CKD-MBD rat models. Furthermore, FPS was shown to directly contribute to the treatment of CKD-MBD by regulating the FGF23-Klotho signaling axis and ERK1/2-SGK1-NHERF-1-NaPi-2a pathway in the kidney.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Ahmed A. Hasan, Carl-Friedrich Hocher, Burkhard Kleuser, Bernhard K. Kraemer, Berthold Hocher
Summary: Preclinical studies have shown that oxidation leads to the loss of biological effects for parathyroid hormone (PTH). Different forms of oxidized PTH (oxPTH) exist, with varying levels of biological activity. The presence and proportions of these different forms in chronic kidney disease (CKD) patients may explain the diverse clinical findings. Current methods for PTH measurement can only distinguish between oxidized and non-oxidized PTH, but not different forms of oxidized PTH. The development of methods that can differentiate between PTH forms has the potential to improve patient care and provide insights into predicting cardiovascular events, mortality, and bone turnover.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
Marciana L. Laster, Bryce Rowan, Hua-Chang Chen, Tae-Hwi Schwantes-An, Xin Sheng, Peter A. Friedman, T. Alp Ikizler, Janet S. Sinshiemer, Joachim H. Ix, Katalin Susztak, Ian H. de Boer, Bryan Kestenbaum, Adriana Hung, Sharon M. Moe, Farzana Perwad, Cassianne Robinson-Cohen
Summary: This study examined the genetic variants associated with mineral metabolism markers in patients with chronic kidney disease (CKD). The findings revealed that the rs4074995 (RGS14) gene variant was associated with lower phosphorus levels, lower plasma FGF23 levels, and a lower prevalence of hyperparathyroidism in CKD patients. This variant was also linked to lower gene expression in the kidney.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Urology & Nephrology
Elizabeth R. Stremke, Gretchen N. Wiese, Sharon M. Moe, Meryl E. Wastney, Ranjani N. Moorthi, Kathleen M. Hill Gallant
Summary: This study showed that there was no significant difference in fractional intestinal phosphorus absorption between patients with moderate CKD and healthy adults, despite lower levels of serum 1,25D. Additionally, the relationship between fractional intestinal phosphorus absorption and 24-hour urine phosphorus was not evident.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Review
Urology & Nephrology
Ayman Al Jurdi, Janaina Da Silva Martins, Leonardo V. Riella
Summary: Bone disease after kidney transplantation is associated with increased risk of fractures, morbidity, and mortality. The pathophysiology is complex and predicting fracture risk remains challenging. The optimal management of this disease has not been established yet, requiring further research to evaluate the efficacy of treatment methods.
SEMINARS IN NEPHROLOGY
(2021)
Article
Medicine, Research & Experimental
Julita Szulimowska, Anna Zalewska, Katarzyna Taranta-Janusz, Daria Trocka, Malgorzata Zendzian-Piotrowska, Ryszard Tomasiuk, Mateusz Maciejczyk
Summary: This case-control study aimed to evaluate the association of ischemia-modified albumin (IMA) in saliva, serum, and urine with the diagnosis of chronic kidney disease (CKD) in children. The results showed that salivary IMA concentration depends on renal function in children and can discriminate children with endstage kidney disease from children with mild and moderate CKD and healthy children with high sensitivity and specificity.
MEDICAL SCIENCE MONITOR
(2023)
Article
Urology & Nephrology
James B. Wetmore, Yuanyuan Ji, Akhtar Ashfaq, David T. Gilbertson, Nicholas S. Roetker
Summary: Analysis of electronic health records of over 50 million patients revealed suboptimal frequency of post-treatment retesting for CKD-MBD patients. Some patients did not undergo necessary testing after treatment, and pretreatment levels of PTH and 25D were not directly associated with likelihood of retesting.
KIDNEY INTERNATIONAL REPORTS
(2021)
Article
Transplantation
Graziella D'Arrigo, Francesca Mallamaci, Patrizia Pizzini, Daniela Leonardis, Giovanni Tripepi, Carmine Zoccali
Summary: This longitudinal study investigated the relationship between repeated measurements of CKD-MBD biomarkers and renal outcomes in CKD patients. The results suggested that serum PTH, calcium, phosphate, FGF23, and 1,25-dihydroxyvitamin D were independently associated with the progression to kidney failure.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Review
Medicine, General & Internal
Ana Pimentel, Jordi Bover, Grahame Elder, Martine Cohen-Solal, Pablo Antonio Urena-Torres
Summary: CKD-MBD is a common complication in patients with CKD, affecting bone health significantly. In addition to biochemical markers, a better understanding of CKD-MBD patterns can help adjust treatment and monitoring strategies.
Review
Endocrinology & Metabolism
Jordi Bover, Pablo Urena-Torres, Mario Cozzolino, Minerva Rodriguez-Garcia, Carlos Gomez-Alonso
Summary: Abnormal bone metabolism is a key aspect of CKD-MBD, with renewed interest in bone as a new endocrine organ and the interaction between bone and vessels. CKD patients have a high risk of osteoporotic fractures, highlighting the need for improved non-invasive approaches to guide treatment decisions.
CALCIFIED TISSUE INTERNATIONAL
(2021)